Viking Phase II Update Shows Sustained Response After Treatment’s End
Currently running a Phase IIb NASH trial with VK2809, Viking reported at EASL that 16-week data in a Phase II study of NAFLD patients showed sustained liver fat reduction after treatment ended.
You may also be interested in...
With resmetirom hitting its co-primary endpoints, Madrigal intends to file the THRβ agonist for approval during H1 2023 in the liver disease, an unmet medical need with blockbuster earnings potential.
While neither company reported new data from their ongoing trials at AASLD, the firm’s competing THRβ agonists are viewed as leading lights in the non-alcoholic steatohepatitis competition.
With Akero’s FGF21 analog showing ability to reduce fibrosis and resolve non-alcoholic steatohepatitis, some analysts think classmate BIO89-100 could yield a better overall profile. NASH data are starting to pour in.